Measurement of Hydroxychloroquine in Blood from SLE Patients Using LC-HRMS-evaluation of Whole Blood, Plasma, and Serum As Sample Matrices

Overview

Journal Arthritis Res Ther

Publisher Biomed Central

Specialty Rheumatology

Date 2020 Jun 2

PMID 32475347

Citations 20

Authors

Henrik Carlsson

Karin Hjorton

Sandy Abujrais

Lars Ronnblom

Torbjorn Akerfeldt

Kim Kultima

Affiliations

Soon will be listed here.

Abstract

Background: Hydroxychloroquine (HCQ) is the standard of care in the treatment of systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and other inflammatory rheumatic diseases and potentially for the treatment in COVID-19 patients. Determination of HCQ for therapeutic drug monitoring (TDM) can be performed in whole blood (WB), serum, and plasma. Direct comparisons of WB, serum, and plasma levels of HCQ in patients with SLE have not previously been reported. We describe a method for the determination of HCQ in human blood using liquid chromatography-high-resolution mass spectrometry (LC-HRMS) and compare the suitability of the three sample matrices.

Methods: A method for the determination of HCQ in human blood using LC-HRMS was developed, validated, and applied for the determination of HCQ levels in WB, serum, and plasma from 26 SLE patients. The reproducibility of the method, in the three matrices, was evaluated using quality control samples and repeated preparations and measurements of patient samples. The performance of the developed method for HCQ measurement in serum was further evaluated by comparison with two previously reported extraction methods.

Results: The performance of the presented method demonstrated high accuracy and precision. A large range of HCQ concentrations was observed for the SLE patients in all three matrices (WB, serum, and plasma). The mean levels in WB were approximately two-fold the levels in serum and plasma (813 ng/mL compared to 436 ng/mL and 362 ng/mL, respectively). Spiked quality controls showed high reproducibility for all matrices (coefficient of variation, CV, approx. 5%), whereas in patient samples, equally high-precision was only found using WB as the matrix (CV 3%). The CV for serum and plasma was 14% and 39%, respectively. Two alternative methods applied to serum samples did not demonstrate improved precision.

Conclusions: A LC-HRMS method for the measurement of HCQ in human blood was developed and validated. Whole blood was found to be the superior sample matrix in terms of sample reproducibility. Thus, whole blood samples should be used for HCQ analysis when patients are monitored for HCQ treatment effects. The assay is in clinical use to monitor levels of HCQ in patients.

Citing Articles

Advancements on the impact of hydroxychloroquine in systemic lupus erythematosus.

Peng-Cheng L, Meng-Na L, Jian-Bin L, Shu-Jiao Y, Wu R Heliyon. 2024; 10(9):e30393.

PMID: 38711668 PMC: 11070867. DOI: 10.1016/j.heliyon.2024.e30393.

Lupus-Induced Accelerated Heart Failure in a Young African American Female: Cardiovascular and Systemic Complications of Noncompliance to Maintenance Therapy and the Social Determinants of Cardiovascular Disease.

Okorie I, Appiah-Kubi E, Owusu-Antwi P, Takyi E, Ugwendum D, Fernando A Cureus. 2024; 16(1):e51819.

PMID: 38327922 PMC: 10847065. DOI: 10.7759/cureus.51819.

Olanzapine Overdose in a Two-Year-Old Girl Resulting in Both High Serum and Plasma Levels.

Yokoyama K, Yakuo T, Mamada M, Nagata M Cureus. 2023; 15(8):e43002.

PMID: 37671213 PMC: 10477032. DOI: 10.7759/cureus.43002.

Janicki P, Singh A, Sharma A, Ruiz-Velasco V Physiol Rep. 2023; 11(14):e15760.

PMID: 37474273 PMC: 10359155. DOI: 10.14814/phy2.15760.

Association Between Severe Nonadherence to Hydroxychloroquine and Systemic Lupus Erythematosus Flares, Damage, and Mortality in 660 Patients From the SLICC Inception Cohort.

Nguyen Y, Blanchet B, Urowitz M, Hanly J, Gordon C, Bae S Arthritis Rheumatol. 2023; 75(12):2195-2206.

PMID: 37459273 PMC: 10792124. DOI: 10.1002/art.42645.

References

Mok C, Penn H, Chan K, Tse S, Langman L, Jannetto P . Hydroxychloroquine Serum Concentrations and Flares of Systemic Lupus Erythematosus: A Longitudinal Cohort Analysis. Arthritis Care Res (Hoboken). 2016; 68(9):1295-302. DOI: 10.1002/acr.22837. View

Durcan L, Clarke W, Magder L, Petri M . Hydroxychloroquine Blood Levels in Systemic Lupus Erythematosus: Clarifying Dosing Controversies and Improving Adherence. J Rheumatol. 2015; 42(11):2092-7. PMC: 4630115. DOI: 10.3899/jrheum.150379. View

Wang L, Ong R, Chin T, Thuya W, Wan S, Wong A . Method development and validation for rapid quantification of hydroxychloroquine in human blood using liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal. 2011; 61:86-92. DOI: 10.1016/j.jpba.2011.11.034. View

Feldman C, Collins J, Zhang Z, Subramanian S, Solomon D, Kawachi I . Dynamic patterns and predictors of hydroxychloroquine nonadherence among Medicaid beneficiaries with systemic lupus erythematosus. Semin Arthritis Rheum. 2018; 48(2):205-213. PMC: 6035896. DOI: 10.1016/j.semarthrit.2018.01.002. View

McLachlan A, Cutler D, Tett S . Plasma protein binding of the enantiomers of hydroxychloroquine and metabolites. Eur J Clin Pharmacol. 1993; 44(5):481-4. DOI: 10.1007/BF00315548. View

Petri M, Purvey S, Fang H, Magder L . Predictors of organ damage in systemic lupus erythematosus: the Hopkins Lupus Cohort. Arthritis Rheum. 2012; 64(12):4021-8. PMC: 3510359. DOI: 10.1002/art.34672. View

Petri M, Orbai A, Alarcon G, Gordon C, Merrill J, Fortin P . Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012; 64(8):2677-86. PMC: 3409311. DOI: 10.1002/art.34473. View

Costedoat-Chalumeau N, Amoura Z, Hulot J, Hammoud H, Aymard G, Cacoub P . Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus. Arthritis Rheum. 2006; 54(10):3284-90. DOI: 10.1002/art.22156. View

Marmor M, Kellner U, Lai T, Melles R, Mieler W . Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision). Ophthalmology. 2016; 123(6):1386-94. DOI: 10.1016/j.ophtha.2016.01.058. View

10.

Costedoat-Chalumeau N, Galicier L, Aumaitre O, Frances C, Le Guern V, Liote F . Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study). Ann Rheum Dis. 2012; 72(11):1786-92. DOI: 10.1136/annrheumdis-2012-202322. View

11.

Smolen J, Landewe R, Breedveld F, Buch M, Burmester G, Dougados M . EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2013; 73(3):492-509. PMC: 3933074. DOI: 10.1136/annrheumdis-2013-204573. View

12.

Balevic S, Cohen-Wolkowiez M, Eudy A, Green T, Schanberg L, Clowse M . Hydroxychloroquine Levels throughout Pregnancies Complicated by Rheumatic Disease: Implications for Maternal and Neonatal Outcomes. J Rheumatol. 2018; 46(1):57-63. PMC: 6314916. DOI: 10.3899/jrheum.180158. View

13.

Fan H, Ma Z, Chen J, Yang X, Cheng J, Li Y . Pharmacokinetics and Bioequivalence Study of Hydroxychloroquine Sulfate Tablets in Chinese Healthy Volunteers by LC-MS/MS. Rheumatol Ther. 2016; 2(2):183-195. PMC: 4883261. DOI: 10.1007/s40744-015-0012-0. View

14.

Pons-Estel G, Alarcon G, Scofield L, Reinlib L, Cooper G . Understanding the epidemiology and progression of systemic lupus erythematosus. Semin Arthritis Rheum. 2009; 39(4):257-68. PMC: 2813992. DOI: 10.1016/j.semarthrit.2008.10.007. View

15.

Munster T, Gibbs J, Shen D, Baethge B, Botstein G, Caldwell J . Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis. Arthritis Rheum. 2002; 46(6):1460-9. DOI: 10.1002/art.10307. View

16.

Tett S, Cutler D, Day R, Brown K . A dose-ranging study of the pharmacokinetics of hydroxy-chloroquine following intravenous administration to healthy volunteers. Br J Clin Pharmacol. 1988; 26(3):303-13. PMC: 1386543. DOI: 10.1111/j.1365-2125.1988.tb05281.x. View

17.

Bengtsson A, Ronnblom L . Systemic lupus erythematosus: still a challenge for physicians. J Intern Med. 2016; 281(1):52-64. DOI: 10.1111/joim.12529. View

18.

Gautret P, Lagier J, Parola P, Hoang V, Meddeb L, Mailhe M . RETRACTED: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020; 56(1):105949. PMC: 7102549. DOI: 10.1016/j.ijantimicag.2020.105949. View

19.

Schrezenmeier E, Dorner T . Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020; 16(3):155-166. DOI: 10.1038/s41584-020-0372-x. View

20.

Balevic S, Green T, Clowse M, Eudy A, Schanberg L, Cohen-Wolkowiez M . Pharmacokinetics of Hydroxychloroquine in Pregnancies with Rheumatic Diseases. Clin Pharmacokinet. 2018; 58(4):525-533. PMC: 6397666. DOI: 10.1007/s40262-018-0712-z. View